Cystic fibrosis heterozygotes do not have increased platelet activation

Inge Tarnow; Alan D. Michelson; Andrew L. Frelinger III; Matthew D. Linden; Youfu Li; Marsha L. Fox; Marc R. Barnard; Brian P. O'Sullivan

doi:10.1016/j.thromres.2007.04.004

Cystic fibrosis heterozygotes do not have increased platelet activation

Inge Tarnow, Alan D. Michelson, Andrew L. Frelinger III, Matthew D. Linden, Youfu Li, Marsha L. Fox, Marc R. Barnard, Brian P. O'Sullivan

1 Citation (Scopus)

Abstract

Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.
Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.
Results: We found no difference in platelet activation between CF heterozygotes and controls.
Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

Original language	English
Journal	Thrombosis Research
Volume	121
Issue number	2
Pages (from-to)	159-162
Number of pages	4
ISSN	0049-3848
DOIs	https://doi.org/10.1016/j.thromres.2007.04.004
Publication status	Published - 2007

Keywords

Former LIFE faculty
Platelets
Cystic fibrosis
Flow cytometry
Cystic fibrosis carriers
Platelet function

Access to Document

10.1016/j.thromres.2007.04.004

Cite this

@article{722b06e0a1c311ddb6ae000ea68e967b,

title = "Cystic fibrosis heterozygotes do not have increased platelet activation",

abstract = "Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.",

keywords = "Former LIFE faculty, Platelets, Cystic fibrosis, Flow cytometry, Cystic fibrosis carriers, Platelet function",

author = "Inge Tarnow and Michelson, {Alan D.} and {Frelinger III}, {Andrew L.} and Linden, {Matthew D.} and Youfu Li and Fox, {Marsha L.} and Barnard, {Marc R.} and O'Sullivan, {Brian P.}",

year = "2007",

doi = "10.1016/j.thromres.2007.04.004",

language = "English",

volume = "121",

pages = "159--162",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Pergamon Press",

number = "2",

}

TY - JOUR

T1 - Cystic fibrosis heterozygotes do not have increased platelet activation

AU - Tarnow, Inge

AU - Michelson, Alan D.

AU - Frelinger III, Andrew L.

AU - Linden, Matthew D.

AU - Li, Youfu

AU - Fox, Marsha L.

AU - Barnard, Marc R.

AU - O'Sullivan, Brian P.

PY - 2007

Y1 - 2007

N2 - Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

AB - Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

KW - Former LIFE faculty

KW - Platelets

KW - Cystic fibrosis

KW - Flow cytometry

KW - Cystic fibrosis carriers

KW - Platelet function

U2 - 10.1016/j.thromres.2007.04.004

DO - 10.1016/j.thromres.2007.04.004

M3 - Journal article

C2 - 17532368

SN - 0049-3848

VL - 121

SP - 159

EP - 162

JO - Thrombosis Research

JF - Thrombosis Research

IS - 2

ER -

Cystic fibrosis heterozygotes do not have increased platelet activation

Abstract

Keywords

Access to Document

Fingerprint

Cite this